Literature DB >> 25755618

Role of liver transplantation for hepatocellular carcinoma.

Vinay Kumaran1.   

Abstract

This review evaluates the available evidence to establish the role of liver transplantation in the management of hepatocellular carcinoma in India. Most liver transplants in India are living donor transplants due to the paucity of brain dead organ donors. There is sufficient evidence to permit allocation of organs to patients with tumors within the Milan criteria. If the waiting list time is more than 6 months, a down-staging locoregional treatment modality such a trans-arterial chemoembolization, radiofrequency ablation, resection or percutaneous ethanol injection may be used to prevent disease progression. Allocating scarce livers to patients with more advanced tumors may not be justifiable. However, living donor liver transplantation may be offered to medically fit patients with hepatocellular carcinoma with cirrhosis, offering a guarded prognosis to patients beyond the Milan or UCSF criteria. Vascular invasion and extra-hepatic disease should be absolute contraindications to liver transplantation.

Entities:  

Keywords:  AFP, alfa-fetoprotein; DDLT, deceased donor transplants; FDG, fluoro-deoxy-glucose; HCC, hepatocellular carcinoma; LDLT, living donor liver transplant; Milan criteria; PET, positron emission tomography; TACE, transarterial chemoembolization; UCSF criteria; hepatocellular carcinoma; liver transplantation; living donor liver transplantation

Year:  2014        PMID: 25755618      PMCID: PMC4284221          DOI: 10.1016/j.jceh.2014.01.002

Source DB:  PubMed          Journal:  J Clin Exp Hepatol        ISSN: 0973-6883


  33 in total

Review 1.  Should we use living donor grafts for patients with hepatocellular carcinoma? Ethical considerations.

Authors:  Elizabeth A Pomfret; J Peter A Lodge; Federico G Villamil; Mark Siegler
Journal:  Liver Transpl       Date:  2011-10       Impact factor: 5.799

2.  Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival.

Authors:  F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

3.  Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma.

Authors:  Toshimi Kaido; Kohei Ogawa; Akira Mori; Yasuhiro Fujimoto; Takashi Ito; Koji Tomiyama; Yasutsugu Takada; Shinji Uemoto
Journal:  Surgery       Date:  2013-09-24       Impact factor: 3.982

4.  Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation.

Authors:  J M Llovet; X Mas; J J Aponte; J Fuster; M Navasa; E Christensen; J Rodés; J Bruix
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

5.  Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma.

Authors:  Christian Toso; James Trotter; Alice Wei; David L Bigam; Shimul Shah; Joshua Lancaster; David R Grant; Paul D Greig; A M James Shapiro; Norman M Kneteman
Journal:  Liver Transpl       Date:  2008-08       Impact factor: 5.799

Review 6.  Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate.

Authors:  Matteo Cescon; Alessandro Cucchetti; Matteo Ravaioli; Antonio Daniele Pinna
Journal:  J Hepatol       Date:  2012-10-04       Impact factor: 25.083

7.  Hepatic transplantation for primary and metastatic cancers of the liver.

Authors:  I Penn
Journal:  Surgery       Date:  1991-10       Impact factor: 3.982

8.  Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis.

Authors:  Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

9.  Role of liver transplantation in cancer therapy.

Authors:  S Iwatsuki; R D Gordon; B W Shaw; T E Starzl
Journal:  Ann Surg       Date:  1985-10       Impact factor: 12.969

10.  Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.

Authors:  Christian Toso; Sonal Asthana; David L Bigam; A M James Shapiro; Norman M Kneteman
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

View more
  10 in total

Review 1.  Hepatocellular carcinoma: Where are we?

Authors:  Roberto Mazzanti; Umberto Arena; Renato Tassi
Journal:  World J Exp Med       Date:  2016-02-20

Review 2.  Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective.

Authors:  Young-In Yoon; Sung-Gyu Lee
Journal:  Dig Dis Sci       Date:  2019-04       Impact factor: 3.199

3.  Indications for living donor liver transplantation in patients with hepatocellular carcinoma.

Authors:  Yasuhiko Sugawara; Yukihiro Inomata
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

4.  Expanding the boundaries of Milan.

Authors:  Catherine Garcia; Luis F Acosta; Roberto Gedaly
Journal:  Hepatobiliary Surg Nutr       Date:  2017-10       Impact factor: 7.293

Review 5.  Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation.

Authors:  Li-Ying Wang; Shu-Sen Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2018-07       Impact factor: 3.066

Review 6.  Overview of Complications in Cirrhosis.

Authors:  Madhumita Premkumar; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2022-05-14

Review 7.  Liver transplantation for advanced hepatocellular carcinoma.

Authors:  Hae Won Lee; Kyung-Suk Suh
Journal:  Clin Mol Hepatol       Date:  2016-09-25

Review 8.  18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma.

Authors:  Arno Kornberg; Martina Schernhammer; Helmut Friess
Journal:  J Clin Transl Hepatol       Date:  2017-07-08

9.  Accuracy of Milan, University of California San Francisco, and Up-To-7 Criteria in Predicting Tumor Recurrence Following Deceased-Donor Liver Transplant in Patients With Hepatocellular Carcinoma.

Authors:  Behnam Saberi; Jacqueline Garonzik-Wang; Michelle Ma; Tokunbo Ajayi; Amy Kim; Harry Luu; Neha Jakhete; Aliaksei Pustavoitau; Robert A Anders; Christos Georgiades; Ihab Kamel; Shane Ottmann; Benjamin Philosophe; Andrew M Cameron; Ahmet Gurakar
Journal:  Exp Clin Transplant       Date:  2018-08-06       Impact factor: 0.945

10.  Interferon-gamma inducible protein 10 (IP10) induced cisplatin resistance of HCC after liver transplantation through ER stress signaling pathway.

Authors:  Wei Geng; Chung-Mau Lo; Kevin T P Ng; Chang-Chun Ling; Xiang Qi; Chang-Xian Li; Yuan Zhai; Xiao-Bing Liu; Yuen-Yuen Ma; Kwan Man
Journal:  Oncotarget       Date:  2015-09-29
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.